These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8584649)

  • 1. Selectivity of MDL 72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma.
    Huebert ND; Schwach V; Hinze C; Haegele KD
    Prog Brain Res; 1995; 106():135-42. PubMed ID: 8584649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72.974A in normal volunteers.
    Hinze C; Harland D; Zreika M; Dulery B; Hardenberg J
    J Neural Transm Suppl; 1990; 32():203-9. PubMed ID: 2089092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates.
    Thomas CE; Huber EW; Ohlweiler DF
    Free Radic Biol Med; 1997; 22(4):733-7. PubMed ID: 9013137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl.
    Terleckyj IA; Heikkila RE
    Ann N Y Acad Sci; 1992 May; 648():365-7. PubMed ID: 1637071
    [No Abstract]   [Full Text] [Related]  

  • 8. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
    Eisenhofer G; Goldstein DS; Stull R; Keiser HR; Sunderland T; Murphy DL; Kopin IJ
    Clin Chem; 1986 Nov; 32(11):2030-3. PubMed ID: 3096593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of aromatic L-amino acid decarboxylase under physiological conditions: optimization of 3-hydroxybenzylhydrazine concentration to prevent concurrent inhibition of monoamine oxidase.
    Hunter LW; Rorie DK; Tyce GM
    Biochem Pharmacol; 1993 Mar; 45(6):1363-6. PubMed ID: 8096696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline.
    Huebert ND; Dulery BD; Schoun J; Schwach V; Hinze C; Haegele KD
    Clin Pharmacol Ther; 1994 Nov; 56(5):537-42. PubMed ID: 7955818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of capsaicin induced airway reflexes in humans: effect of monoamine oxidase inhibition.
    Choudry NB; Studham J; Harland D; Fuller RW
    Br J Clin Pharmacol; 1993 Feb; 35(2):184-7. PubMed ID: 8443037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.
    Stoltz M; Reynolds D; Elkins L; Salazar D; Weir S
    Clin Pharmacol Ther; 1995 Sep; 58(3):342-53. PubMed ID: 7554709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
    Zreika M; Fozard JR; Dudley MW; Bey P; McDonald IA; Palfreyman MG
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):243-54. PubMed ID: 2597310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma.
    Hovevey-Sion D; Kopin IJ; Stull RW; Goldstein DS
    Neuropharmacology; 1989 Aug; 28(8):791-7. PubMed ID: 2506486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assay of catecholamines and dihydroxyphenylethyleneglycol in human plasma and its application in orthostasis and mental stress.
    Halbrügge T; Gerhardt T; Ludwig J; Heidbreder E; Graefe KH
    Life Sci; 1988; 43(1):19-26. PubMed ID: 3386411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between age and venous plasma concentrations of noradrenaline, catecholamine metabolites, DOPA and neuropeptide Y-like immunoreactivity in normal human subjects.
    Hetland ML; Eldrup E; Bratholm P; Christensen NJ
    Scand J Clin Lab Invest; 1991 May; 51(3):219-24. PubMed ID: 1909048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.
    Illi A; Sundberg S; Koulu M; Scheinin M; Heinävaara S; Gordin A
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):582-8. PubMed ID: 7874370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.